CPC A61K 39/3955 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 31/522 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); C07K 16/2866 (2013.01); G06N 20/00 (2019.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01)] | 48 Claims |
1. A method of treating a subject with an anti-interleukin-4 receptor alpha (anti-IL-4Rα) antibody, comprising administering a therapeutically effective amount of an anti-IL-4Rα antibody to a subject exhibiting at least one symptom of a disorder selected from the group consisting of an esophageal-related disorder, a lung-related disorder, a blood-related disorder, a gastrointestinal-related disorder, a kidney-related disorder, a prostate-related disorder, Kawasaki's disease, a thyroid-related disorder, a blood-vessel-related disorder, a pregnancy-related disorder, and a cancer,
wherein the anti-IL-4Rα antibody comprises:
a variable heavy chain CDR1 of SEQ ID NO:1 (GFTFRDYA);
a variable heavy chain CDR2 of SEQ ID NO:2 (ISGSGGNT);
a variable heavy chain CDR3 of SEQ ID NO:3 (AKDRLSITIRPRYYGLDV);
a variable light chain CDR1 of SEQ ID NO:4 (QSLLYSIGYNY);
a variable light chain CDR2 of SEQ ID NO:5 (LGS); and
a variable light chain CDR3 of SEQ ID NO:6 (MQALQTPYT).
|